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The aminothiol drug WR2721 (amifostine, Ethyol), and
its free-thiol metabolite WR1065, are cytoprotective
agents. Ethyol is licensed to attenuate toxicity in cancer
patients receiving chemo- and radiation-therapy. We
found that WR1065 mitigates Zidovudine (AZT)-induced
mutagenesis, and designed studies to ascertain that AZT
antiretroviral activity was not altered in the presence of
this aminothiol. Fresh peripheral blood mononuclear
cells were cultured with phytohemaglutinin (PHA) for 48
hr. The resulting PHA-stimulated blasts were infected for
2 hr with HIV-1BZ-167 before the addition of AZT,
WR1065, or Ethyol dephosphorylated by preincubation
with alkaline phosphatase. Cells were cultured for an
additional 72 hr and assayed for cytotoxicity (trypan blue)
and HIV-1 replication (p24 ELISA kit). AZT concentra-
tions of 0.8, 3.0, and 5.0 μM inhibited virus replication by
85–96%, and the same AZT doses combined with 5–26
μM WR1065 inhibited virus replication by 91–97%.
When tested alone, AZT at 7.75 μM inhibited virus repli-
cation by 96.7 ± 5.1% (mean ± SD, n = 4) with 54 ± 15%
target cell survival. Ethyol at 50 μM inhibited virus repli-
cation by 75.4 ± 16.6% (mean ± SD, n = 4) and cell sur-
vival was 53 ± 19%. Similarly, WR1065 concentrations of
50 and 100 μM blocked virus replication by 83.2 ± 18.6%
(n = 5) and 92.0 ± 11.0% (n = 5), respectively, with cell
survival at 55 ± 22% and 42 ± 18%, respectively. The data
show that Ethyol and WR1065 do not compromise the
antiretroviral efficacy of AZT. Interestingly, when used
alone, these aminothiols also substantially inhibit HIV-1
replication. (Supported in part by R01 CA95741 to VEW;
patent pending).
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